Medical specialties

World's First FDA IDE Coronary Patient Treated With a DEB

Saturday, July 11, 2020 - 8:00am

This is the first DEB accepted by the FDA for its 'Breakthrough Program'.

Key Points: 
  • This is the first DEB accepted by the FDA for its 'Breakthrough Program'.
  • "This first patient was treated with the investigational device after suffering a DES ISR.
  • We are delighted to be able to offer our patients this promising new technology," commented Professor Pascal Vranckx, Hartcentrum Hasselt, Belgium.
  • "No coronary drug-eluting balloon has yet been approved in the US, where ISR currently represents 11% of all stent implantations.

Akerna Flash Report: Can Oil Day Beat the Sales Record Set by the 4th of July Weekend?

Friday, July 10, 2020 - 9:05pm

Historically, oil sales have seen a 124% increase on 7/10 compared to the daily average for the rest of the year.

Key Points: 
  • Historically, oil sales have seen a 124% increase on 7/10 compared to the daily average for the rest of the year.
  • Over the 4th of July weekend, Friday, July 3 was the highest sales day for cannabis in 2020.
  • Sales over the holiday weekend broke down as follows:
    "It was interesting to see 86% of sales were in store.
  • At the height of COVID we tracked a steady trend in pickup and delivery as product fulfillment methods," said Ahrendt.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Friday, July 10, 2020 - 10:00pm

The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The awards are subject to the terms and conditions of Mirums 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • The companys lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

LeMaitre Vascular Will Announce Second Quarter 2020 Earnings Results on July 23, 2020

Friday, July 10, 2020 - 8:11pm

BURLINGTON, Mass., July 10, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc.(Nasdaq:LMAT) announced today that it will release its second quarter 2020 financial results onThursday, July 23, 2020, after the market close.

Key Points: 
  • BURLINGTON, Mass., July 10, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc.(Nasdaq:LMAT) announced today that it will release its second quarter 2020 financial results onThursday, July 23, 2020, after the market close.
  • The company has scheduled a conference call for5:00 PM EDTthe same day to discuss the results, business highlights, and company outlook.
  • LeMaitre Vascularis a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide.
  • The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

Dynavax and Times Pharmacy Announce Partnership to Offer HEPLISAV-B® Hepatitis B Vaccine to Customers Throughout Oahu, with a Focus on People with Diabetes

Friday, July 10, 2020 - 9:01pm

Through this partnership, pharmacy customers will have access to HEPLISAV-B, the only FDA-approved two-dose hepatitis B vaccine for adults that is completed in one month.

Key Points: 
  • Through this partnership, pharmacy customers will have access to HEPLISAV-B, the only FDA-approved two-dose hepatitis B vaccine for adults that is completed in one month.
  • Preventing hepatitis B through immunization is an important part of preventive care and is critical to slowing the spread of hepatitis B, which will also help protect against new cases of liver cancer.
  • Hepatitis B is a liver infection caused by the hepatitis B virus (HBV).
  • HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

Trump Kidney Care Executive Order Remembered On First Anniversary

Friday, July 10, 2020 - 7:07pm

WASHINGTON, July 10, 2020 /PRNewswire/ --The American Association of Kidney Patients (AAKP) today issued a patient editorial on the first anniversary of the Executive Order on Advancing American Kidney Health Initiative , signed by President Donald Trump on July 10, 2019.

Key Points: 
  • WASHINGTON, July 10, 2020 /PRNewswire/ --The American Association of Kidney Patients (AAKP) today issued a patient editorial on the first anniversary of the Executive Order on Advancing American Kidney Health Initiative , signed by President Donald Trump on July 10, 2019.
  • The sweeping Executive Order calls for an end to status quo kidney care in in the United States, which has been plagued by extremely high mortality rates, lack of medical innovation, limited utilization of home dialysis, and barriers to kidney transplantation.
  • AAKP President Richard Knight, a 14-year kidney transplant patient stated, "The Executive Order on Advancing American Kidney Health launched the most substantive, bipartisan, and optimistic change in American kidney policy in over 50 years.
  • About the American Association of Kidney Patients (AAKP): AAKP is theoldest and largestkidney patient advocacy organization in the United States.

Mississippi Activist Takes Action After First West Nile Case Announced

Friday, July 10, 2020 - 6:00pm

The state of Mississippi officially announced its first case of West Nile virus in 2020, and, as mosquito season intensifies, WEEP aims to protect people from the deadly predators in their own backyards.

Key Points: 
  • The state of Mississippi officially announced its first case of West Nile virus in 2020, and, as mosquito season intensifies, WEEP aims to protect people from the deadly predators in their own backyards.
  • After he lost his son, Phillip, to a West Nile virus-related illness, Hendry made mosquito virus education his lifelong mission.
  • Even in the midst of the COVID outbreak, Hendry hopes that members of the Mississippi community will take the West Nile virus seriously.
  • WEEP & Recover is a registered 501-c3 organization dedicated to providing information about West Nile Virus prevention and eradication.

Global Market for Surgical Hemostats, Internal Tissue Sealants and Adhesion Barriers 2020-2027 - ResearchAndMarkets.com

Friday, July 10, 2020 - 5:04pm

The "Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers estimated at US$3.5 Billion in the year 2020, is projected to reach a revised size of US$5.9 Billion by 2027, growing at a CAGR of 7.6% over the analysis period 2020-2027.
  • This segment currently accounts for a 31.7% share of the global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers market.
  • The U.S. Accounts for Over 27% of Global Market Size in 2020, While China is Forecast to Grow at a 11.6% CAGR for the Period of 2020-2027
    The Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers market in the U.S. is estimated at US$947 Million in the year 2020.

Worldwide Cystic Fibrosis Industry to 2024 - Develop In-Depth Knowledge of Competition and Markets - ResearchAndMarkets.com

Friday, July 10, 2020 - 4:48pm

This report provides comprehensive insights into the Cystic Fibrosis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.

Key Points: 
  • This report provides comprehensive insights into the Cystic Fibrosis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Cystic Fibrosis market size and drug sales.
  • This research covers the following: Cystic Fibrosis treatment options, Cystic Fibrosis late stage clinical trials pipeline, Cystic Fibrosis prevalence by countries, Cystic Fibrosis market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Cystic Fibrosis pipeline: Find out drugs in clinical trials for the treatment of Cystic Fibrosis by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Cystic Fibrosis drugs: Identify key drugs marketed and prescribed for Cystic Fibrosis in the US, including trade name, molecule name, and company
    Cystic Fibrosis market valuations: Find out the market size for Cystic Fibrosis drugs in 2019 by countries.

Company Profile for Reven, LLC

Friday, July 10, 2020 - 3:40pm

Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado, based operating company Reven, LLC, is a biopharmaceutical company.

Key Points: 
  • Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado, based operating company Reven, LLC, is a biopharmaceutical company.
  • Revens vision is to make a difference in the world by making its products accessible to everyone suffering the effects of vascular and metabolic related diseases.
  • Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world.
  • Its primary product, Rejuveinix (RJX), targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering PAD and other cardiovascular related medical conditions.